US FDA’s Califf Expects Advisory Committee Reform Talk ‘About A Year From Now’
Executive Summary
The FDA commissioner said several aspects of the advisory committee system should be considered for updates or adjustment. A revamp effort has predated his return trip to the agency.
You may also be interested in...
US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time
FDA Commissioner Califf and some top deputies are angling for more advisory panels that would influence drug development programs rather than approval decisions. Califf also wants to adjust meeting formats so advisors have more time for in-depth discussions.
US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time
FDA Commissioner Califf and some top deputies are angling for more advisory panels that would influence drug development programs rather than approval decisions. Califf also wants to adjust meeting formats so advisors have more time for in-depth discussions.
FDA Advisory Committees Continue To Come Under Congressional Scrutiny
Rep. Anna Eshoo, the ranking Democrat on the House Energy and Commerce health subcommittee suggested FDA and CDC vaccine advisory committees contributed to the public’s confusion during the pandemic response.